India Glycols Limited
Established in 1988, India Glycols Ltd. is engaged in the manufacturing of green technology-based bulk, specialty & performance chemicals, and natural gums, spirits, industrial gases, sugar, and nutraceuticals.
What India files
- Others80
- Important56
- Investor Meet28
- PPTs12
- Updates11
- Dividend/Bonus9
India Glycols has successfully demerged, creating three independent entities and allowing the parent company to sharpen its focus on bio-based specialty materials, sustainable performance chemicals, and gases. Post-demerger, the retained business reported FY26 net sales of ₹1,164 Cr, a decline from FY24's ₹1,581 Cr. However, Adjusted EBITDA significantly grew to...
India Glycols Limited (IGL) is undergoing a significant transformation post-demerger, now sharply focused on sustainable specialty chemicals. The demerger became effective on September 1, 2026, creating three independent entities for improved focus and capital allocation. **Business Performance:** For the retained IGL business, FY26 net sales were ₹1,164 Cr. While revenue...
IGL Spirits demonstrates strong performance, with total revenue growing at a 39% CAGR (FY24-26) to ₹2,801 Cr in FY26, driven by robust potable spirits and bio-fuels segments. EBITDA surged at a 48% CAGR (FY24-26) to ₹492 Cr, while potable spirits gross margins significantly improved to 45.9%. The company achieved a...
Ennature Biopharma, a natural ingredients platform, reported revenue of INR 246 Cr and EBITDA of INR 29 Cr for its recent fiscal year. The Plant-based API segment is the largest, contributing 67% of sales and providing stable cash flow, while Nutraceuticals (17%) and Biopolymers (16%) are key growth areas. The...
IGL had a robust Q1FY27. Consolidated Net Revenue rose 8.6% YoY to ₹1,130 Cr, EBITDA jumped 12.5% to ₹170 Cr, and PAT soared 32.2% to ₹97 Cr. Ennature Biopharma led growth (+65% revenue), followed by Chemicals (+21%) and Potable Spirits (+5%). Biofuel revenue dipped but EBIT improved. The NCLT-approved demerger...